Thrombotic thrombocytopenic purpura (TTP) is a disorder characterized by thrombotic microangiopathy, thrombocytopenia, and microvascular thrombosis that can cause various degrees of tissue ischemia and infarction. Clinically, TTP patients are diagnosed by signs and symptoms such as thrombocytopenia, microangiopathic hemolytic anemia, neurological abnormalities, renal failure, and fever (1, 2). In 1982, Moake et al. found ultra-large von Willebrand factor (UL-VWF) multimers in the plasma of patients with chronic relapsing TTP (3). Most patients suffering from TTP are deficient in a plasma metalloprotease that cleaves UL-VWF (4–9). The protease belongs to the ADAMTS (a disintegrin-like and metalloprotease with thrombospondin type I repeats) family and is designated as ADAMTS13, a 190-kD glycosylated protein produced predominantly by the liver (10–12), specifically by hepatic stellate cells (13, 14). Mutations in the ADAMTS13 gene have been shown to cause familial TTP (10). Acquired TTP, often caused by autoantibodies inhibiting ADAMTS13 activity, is a more common disorder that occurs in adults and older children and can recur at regular intervals in 11–36% of patients (4, 6). Nonneutralizing autoantibodies have been associated with acute acquired TTP (15). In most patients with familial or acquired TTP, plasma ADAMTS13 activity is absent or <5% of normal.

Without treatment, the mortality rate exceeds 90%, but plasma exchange therapy has reduced mortality to ~20% (2).

VWF synthesized in megakaryocytes and endothelial cells is stored in platelet α-granules and Weibel-Palade bodies, respectively, as UL-VWF (16). Once secreted from endothelial cells, these UL-VWF multimers are cleaved by ADAMTS13 in the circulation into a series of smaller multimers at specific cleavage sites within the VWF molecule (17–19). The protease cleaves at the Tyr842–Met843 bond in the central A2 domain of the mature VWF subunit (20) and requires zinc and calcium for activity. VWF exists in “ball of yarn” and filamemtous globular form.
forms as seen by electron microscopy (21). Furthermore, atomic force microscopy confirms that VWF exists in a globular conformation under static conditions and may unfold to a filamentous state after exposure to shear stress (22). This could occur also in vivo when one end of the VWF filament is anchored to a surface. UL-VWF multimers have high biological activity. They bind better to the extracellular matrix than regular multimers (23) and form higher strength bonds with platelet GPIb-IX than plasma VWF (24). It was demonstrated in vitro that platelets align as beads on the released UL-VWF string on the endothelial surface. These strings are then cleaved by ADAMTS13 and released from the stimulated endothelial cells (25). We have demonstrated in vivo that it is only in Adamts13−/− mice that strings of platelets remain intact after endothelial activation in veins (26). These strings attach at one end to endothelium and “wave” the other end in the blood stream.

Thrombi of TTP patients consist of a little fibrin but mainly of VWF and platelets, suggesting VWF-mediated platelet aggregation as a cause of thrombosis (27). We hypothesized that endothelial activation resulting in elevation of hyperactive UL-VWF multimers in plasma could be associated with an increased risk of thrombosis in ADAMTS13-deficient animals. We investigated thrombosis in venules and arterioles of Adamts13−/− mice by intravital microscopy. Our findings strongly suggest that ADAMTS13 has natural antithrombotic activity and that recombinant human (r-hu) ADAMTS13 could be used to treat TTP and possibly other thrombotic conditions.

RESULTS

Endothelial activation results in thrombi formation in microvenules of Adamts13−/− mice

We have previously observed that platelet sticking/translocation in venules of 200–250 μm in diameter activated with calcium ionophore A23187 (a secretagogue of Weibel-Palade bodies) at low shear rate (∼100 s−1) was prolonged in Adamts13−/− mice compared with Adamts13+/+ mice (26). We investigated whether activation of microvenule endothelium by A23187 (which does not denude the endothelium; reference 28) results in platelet aggregation and subsequent thrombus formation. The shear rate (200–250 s−1) and diameter of all the microvenules (25–30 μm) studied were similar for Adamts13−/− and Adamts13+/+ mice (Table I). In the microvenules of Adamts13−/− mice, platelet aggregation resulting in thrombus formation was observed from 45 s to 2 min after topical superfusion of A23187 (Fig. 1). The thrombi were often unstable and flushed away, leading to frequent embolization and causing transient downstream occlusion usually only lasting 3–4 s. Thus, stimulation of Weibel-Palade body secretion can lead to spontaneous thrombus formation in Adamts13−/− mice in the absence of vascular injury. In Adamts13+/+ mice treated identically, platelet strings and very small platelet aggregates could be seen attached to the

- Table I. Hemodynamic parameters were established before application of A23187 (Fig. 1) on venules and FeCl₃ on arterioles (Fig. 5)

- Figure 1. Thrombus formation in stimulated microvenules of Adamts13−/− mice. Venules measuring ∼25–30 μm in diameter were visualized in the mesentery of live mice. 1 min after topical superfusion of calcium ionophore A23187, thrombus formation was observed in Adamts13−/− mice (n = 5). No microthrombi formed in Adamts13+/+ mice treated identically (n = 5). Arrows indicate the microthrombi. See Video 1 (available at http://www.jem.org/cgi/content/full/jem.20051732/DC1) for thrombi in the microvenules of Adamts13−/− mice.

- Baseline 1 min after A23187 2 min after A23187

- Adams13+/+

- Adams13−/−
endothelium for 1–2 s, but thrombi did not form. These observations demonstrate that ADAMTS13 is active at low shear and, thus, inhibits platelet aggregation and prevents thrombus formation in the microvenules. In addition, arterioles (high shear) running parallel to the venules in either Adamts13−/− or Adamts13+/+ mice did not show any platelet strings, platelet aggregation, or thrombus formation.

An antibody to ADAMTS13 prolongs adhesion of platelets to secreted VWF on the vessel wall of Adamts13+/+ mice

Previous studies have shown that most patients suffering from the acquired form of TTP have autoimmune inhibitors to ADAMTS13 in plasma (4, 6). We infused a polyclonal anti-human ADAMTS13 antibody in Adamts13+/+ mice 2 h before surgical preparation for intravital microscopy. The antibody did not activate the endothelium as normal baseline platelet adhesion was found in Adamts13+/+ mice after its infusion (Fig. 2). After topical superfusion of A23187, many platelets stuck/translocated on the endothelium, reaching a peak of platelet adhesion from 45 s to 1 min that progressively decreased with time. However, more platelet sticking was observed 4 min after the A23187 application in the antibody-infused Adamts13+/+ as compared with control Adamts13+/+ mice (control IgG [n = 2] or PBS [n = 5]) (Fig. 2). The phenomenon observed was similar to that observed in Adamts13−/− mice (26). Strings of platelets were seen varying from 20 to 40 μm and attached at one end to the endothelium and waving in the bloodstream. These strings

![Figure 2. Antibody to ADAMTS13 increases platelet adhesion and string formation on activated vessel wall.](image)

Figure 2. Antibody to ADAMTS13 increases platelet adhesion and string formation on activated vessel wall. Fluorescently labeled platelets representing ~2.5% of total platelets were observed in mesenteric venules (diameter: 200–250 μm) of live mice before (baseline) and after A23187 superfusion. Platelets began to adhere to the endothelium 30–45 s after superfusion. In Adamts13+/+ mice (infused with anti-human ADAMTS13 Ab, n = 4), more platelets adhered to the vessel wall 4 min after stimulation compared with Adamts13+/+ control (n = 4). Arrows indicate the ≥20-μm strings of platelets attached at one end to the endothelium and waving the other end in the blood stream. Inset time points in the lower right corner refer to the time after superfusion of A23187. The bar shown in the middle panel is ~50 μm.

![Figure 3. Thrombus formation in microvenules of Adamts13+/+ mice infused with an anti-ADAMTS13 antibody.](image)

Figure 3. Thrombus formation in microvenules of Adamts13+/+ mice infused with an anti-ADAMTS13 antibody. Mesenteric venules of ~25–30-μm in diameter were observed. 1 min after topical superfusion with A23187, thrombus formation was observed in four out of six Adamts13+/+ mice infused with the anti-ADAMTS13 Ab. The microthrombi formation and embolization were similar to that seen in Adamts13−/− mice (Fig. 1). Arrows indicate a microthrombus. Microthrombi did not form in Adamts13+/+ control (n = 5).
were either not seen or were very short lived (<2 s) in the Adamts13+/− mice.

ADAMTS13 inhibitor induces thrombi formation in microvenules of Adamts13+/− mice

In the Adamts13+/+ mice infused with anti-human ADAMTS13 antibody 2 h before surgical preparation, microthrombi formed on the vessel wall 45 s to 1 min after topical superfusion of A23187 in four out of six mice (Fig. 3). The microthrombi appearance was similar to those seen in the Adamts13−/− mice (Fig. 1). In control Adamts13+/+ mice, short-lived platelet strings could be seen attached to the endothelium, but they did not result in thrombus formation (n = 5).

Histamine promotes platelet string formation in the venules of Adamts13−/− mice, a process inhibited by recombinant ADAMTS13

Histamine produced during inflammation is a secretagogue of Weibel-Palade bodies and stimulates the endothelium (29). We investigated whether activation of venules by injecting histamine i.p. into Adamts13−/− mice could result in platelet strings. Endogenous platelets were labeled by infusing Rhodamine 6G i.v. before surgery. Histamine was injected i.p. 15 min before the surgical preparation into Adamts13−/− (n = 5) and Adamts13+/+ (n = 5) mice and venules at a shear rate of ~100 s−1 were visualized. In the Adamts13+/+ mice, strings of platelets were not seen or were short lived (<5 s; Fig. 4 A), whereas, in the Adamts13−/− platelet strings, varying from 20 to 100 μm could be seen (Fig. 4 B) anchored to the endothelium for ~1 min. In some mice, the platelet strings persisted for up to 5 min. Some strings appeared to coalesce, forming aggregates (Fig. 4 C) that were later released into the blood stream. Infusion of r-hu ADAMTS13 protein in the Adamts13−/− mice (n = 4; 3 venules per mouse) inhibited platelet string formation in all venules examined (Fig. 4 D), thus demonstrating the activity of ADAMTS13 at low shear.

Platelet binding to subendothelium is increased in Adamts13−/− mice

Ferric chloride (FeCl3) injury leads to deendothelialization and exposes subendothelium (30). Platelet subendothelial interactions after injury at arterial shear are initiated by GPIb–VWF interaction and propagated by other receptors (30). In both Adamts13+/+ and Adamts13−/− mice, platelet–vessel wall interaction started rapidly after FeCl3 application to the arteriole. The number of animals in which >100 fluorescent platelets were deposited 2–3 min after injury was higher in Adamts13−/− mice. In the Adamts13−/−, 7 out of 12 mice showed >100 platelets deposited on the vessel wall compared with 3 out of 10 in the Adamts13+/+ mice (P < 0.05, Fig. 5 A).

Thrombus formation is accelerated in injured arterioles of Adamts13−/− mice

After finding that ADAMTS13 negatively modulates resting platelet adhesion to both stimulated endothelium and subendothelium, we asked whether the enzyme affects arteriolar thrombus formation. This process requires platelet activation and employs several ligands aside from VWF (30). The shear rate and diameter of arterioles studied were similar for Adamts13−/− and Adamts13+/+ mice (Table I). In the Adamts13−/− mice, thrombi grew faster as thrombi >30 μm were seen at 6.64 ± 0.93 min compared with 10.78 ± 0.80 min in the Adamts13+/+ mice (P < 0.005, Fig. 5 B). This suggests that cleavage of VWF multimers by ADAMTS13 delays thrombus formation. The thrombi grew to occlusive size in 10.56 ± 0.72 min in Adamts13−/−, whereas in Adamts13+/+ all the vessels were still open at this time (Fig. 5, C and D). In the Adamts13+/+, the mean vessel occlusion time was 16.69 ± 1.25 min after injury (P < 0.0005). All the vessels occluded at the site of injury. Of note, in arterioles of Adamts13−/− mice, the mean time for formation of thrombi (30 μm) as well as the mean occlusion time were less than that of any individual Adamts13+/+ mouse (Fig. 5, B and C).

ADAMTS13 deficiency enhances thrombus growth in an αIIBβ3 integrin-dependent manner

To study the importance of integrin αIIBβ3 for thrombus formation in the absence of ADAMTS13, we performed in vitro flow chamber studies with whole blood in the presence or absence of a blocking antibody (JON/A) against αIIBβ3 (31) (Fig. 6). To quantify the size of the thrombi, the surface area covered by fluorescently labeled platelets was determined. As expected, Adamts13−/− blood formed significantly...
larger thrombi than *Adamts13*+/+ when perfused over collagen for 2 min at a shear rate of 1,500 s⁻¹ (44.66 ± 3.63% vs. 20.22 ± 3.88%; P < 0.0005), demonstrating again the key role of *ADAMTS13* in limiting thrombus growth. In the presence of the blocking antibody to αIIbβ₃, only single platelets adhered to the collagen surface and thrombus formation was completely inhibited in both the *Adamts13*+/+ and *Adamts13*−/− blood (3.01 ± 0.97% vs. 2.82 ± 0.39%; P > 0.05).

In addition, we tested whether infusion of r-hu ADAMTS13 inhibitory antibody into β₃ integrin-deficient mice (32) would induce thrombus formation after FeCl₃ injury. We could not detect any thrombi in injured arterioles of β₃−/− mice (three animals were evaluated) despite the presence of the anti-ADAMTS13 antibody (unpublished data). Collectively, these results indicate that, at the arterial shear rates, UL-VWF enhances thrombus growth in an αIIbβ₃-dependent manner.

**Figure 5.** Quantitative analysis of platelet adhesion and thrombus formation in FeCl₃-injured arterioles of *Adamts13*+/+ and *Adamts13*−/− mice. (A) The number of fluorescent platelets deposited per minute was determined in the interval 2–3 min after injury. Absence of ADAMTS13 in the plasma significantly increases early platelet interaction with the subendothelium (P < 0.05). (B) Thrombi (>30 μm) appeared sooner in *Adamts13*−/− mice compared with *Adamts13*+/+ (P < 0.005). (C) The occlusion time (blood flow completely stopped for 10 s) was determined. Both *Adamts13*+/+ and *Adamts13*−/− mice occluded at the site of injury; however, in *Adamts13*−/− mice, occlusion time was shorter as compared with *Adamts13*+/+ mice (P < 0.0005). (D) Fluorescently labeled platelets representing ~2.5% of total platelets were observed in mesenteric arterioles of live mice after FeCl₃ injury. Single adherent platelets are seen in the arteriole at 4 min after injury in the *Adamts13*+/+ mouse, whereas a thrombus (~30 μm) can already be seen in the *Adamts13*−/− mouse at the same time point. The vessel was occluded at 10 min at the site of injury in the *Adamts13*−/− mouse, whereas the *Adamts13*+/+ mouse arteriole remained opened at that time. Representative figures are shown. Blood flow was from left to right.

**Infusion of r-hu ADAMTS13 into *Adamts13*−/− or wild-type (C57BL/6J) mice inhibits thrombus growth by destabilizing the platelet aggregate**

In vitro, r-hu ADAMTS13 cleaves human VWF (18) and mouse plasma VWF into proteolytic fragments with the same efficiency (unpublished data). It has been demonstrated that r-hu ADAMTS13 corrects the VWF cleavage defect in hereditary TTP plasma (33). Because we observed accelerated growth of thrombi in *Adamts13*−/− mice, we hypothesized that ADAMTS13 negatively modulates thrombus growth and, therefore, infusion of r-hu ADAMTS13 could delay thrombus formation. We infused r-hu ADAMTS13 into mice and determined that the concentration of the circulating human protein was ~8.8 U/ml at 17 min after infusion and 1.1 U/ml at 53 min after infusion. These times correspond approximately to the onset of FeCl₃ injury and the termination of the experiment. We examined first whether the prothrombotic phenotype of *Adamts13*−/− mice could be reversed. In 5 out
of 13 Adams13+/− mice infused with r-hu ADAMTS13, injured arterioles did not occlude for up to 40 min when the experiment was terminated (Fig. 7 A). The effect of the infused r-hu ADAMTS13 was more than that of endogenous ADAMTS13 in Adams13+/+ mice; as in this injury model, all Adams13+/+ vessels occluded at <24 min (Fig. 5 C). The mean occlusion time was significantly prolonged in comparison with the control mice infused with buffer (P < 0.0005). In all the mice whose arterioles did not occlude, thrombi formed but were unstable and dissolved (Fig. 7 C). This phenomenon of thrombi formation and destabilization was present during the entire period of observation.

To examine whether r-hu ADAMTS13 could delay occlusion in injured arterioles of mice with normal levels of the endogenous ADAMTS13 protein, we infused the recombinant protein in C57BL/6J wild-type mice before injury. The infused protein caused significant delay in occlusion time with half of the arterioles not occluding by 40 min, whereas all arterioles of wild-type mice infused with vehicle occluded by 15 min (Fig. 7 B, P < 0.008). Thus, ADAMTS13 appears to have a significant antithrombotic potential even in wild-type animals.

DISCUSSION

The studies presented here have defined a key role for ADAMTS13 in preventing thrombi formation in activated microvenules and excessive thrombus formation in the injured arterioles of mice. Our in vivo findings of microvascular thrombosis caused by stimulated release of VWF are consistent with the observation that patients suffering from TTP have thrombi rich in platelet aggregates and VWF (27). It was suggested that, in the development of TTP, microvascular endothelial activation could be the primary event initiating platelet aggregation in the arterioles and capillaries (2). Various agents, including viruses, bacterial shiga toxins, drugs such as ticlopidine and clopidogrel, antibodies, and immune complexes, can trigger vascular activation (34), perhaps inducing Weibel-Palade body release. We did not see thrombi in the arterioles (which have higher shear stress) treated identically with A23187. This is because either Weibel-Palade bodies were not released in these vessels or, more likely, VWF is washed too quickly from the endothelial surface to promote platelet adhesion. Venous thrombosis is not generally recognized as a pathologic characteristic of TTP in human patients and was also not a prominent feature of spontaneous or shigatoxin-induced TTP in the Adams13−/− mouse (26). These observations suggest that formation of platelet-rich microthrombi in the venous circulation in the setting of acute TTP is either subclinical or transient, or counterbalanced by other regulatory processes that are not as effective in the arteriovascular lumen.

Autoantibodies neutralizing human ADAMTS13 are the major cause of acquired TTP. Various epitopes of the ADAMTS13 protein are recognized by the autoantibodies (35, 36). Infusion of anti-ADAMTS13 antibody in the Adams13+/+ mice resulted in prolonged adhesion of platelets to secreted VWF and platelet string formation on the stimulated endothelium (Fig. 2) that was similar to that seen in the Adams13−/− mice (26). It was shown that P-selectin may anchor the newly released UL-VWF multimers in vitro (37); however, this remains to be confirmed in vivo. Platelet strings and aggregates were frequently seen in the Adams13−/− mouse when challenged with Weibel-Palade body secretagogues (unpublished data) such as histamine (38), the inflammatory cytokine TNF-α (39), or activated platelets (40). This suggests that in patients lacking functional ADAMTS13, TTP could be precipitated by inflammation, by allergic responses, or by situations leading to platelet activation. Infusion of anti-ADAMTS13 antibody into Adams13+/+ mice with activated microvenules resulted in platelet aggregation and thrombi formation (Fig. 3). However, these thrombi embolized rapidly, similar to those in the Adams13−/− mice. Thus, the mouse infused with anti-ADAMTS13 antibody represents a new animal model for acquired TTP.
Our observations that endothelial activation of microvenules results in thrombi in the Adamts13−/− mice led to the hypothesis that ADAMTS13 deficiency might accelerate thrombus formation in injured arterioles. Indeed, the absence of ADAMTS13 promoted all aspects of thrombus growth. Unexpectedly, even more platelets were deposited on the denuded vessel wall after 2–3 min of injury in the Adamts13−/− mice as compared with Adamts13+/+ (Fig. 5 A). Because early platelet deposition in arterioles is VWF dependent (30), it means that either plasma ADAMTS13 reduces VWF incorporation into the basement membrane when it is exposed to blood or that it digests VWF already present in the extracellular matrix. The rapid thrombus growth and occlusion in Adamts13−/− mice indicates that ADAMTS13 might cleave VWF multimers incorporated in the thrombus. It has been suggested that cleavage of VWF domain A2 by ADAMTS13 is facilitated by the binding of VWF to GPIbα (41). Thus, the VWF–GPIb interaction within the thrombus may negatively regulate thrombus growth. Thrombus formation under venous and arterial flow conditions also depends on major integrin αIIbβ3 (42, 43). Our studies at arteriolar shear rates show that ADAMTS13 modulates the growing thrombus only when platelets in the thrombus express an active β3 integrin. Under our in vitro and in vivo experimental conditions, ADAMTS13 deficiency did not promote thrombus growth if the major platelet integrin was absent or inhibited (Fig. 6).

To inhibit the fast thrombus growth seen in the Adamts13−/− mice, we infused r-hu ADAMTS13 into the Adamts13−/− and wild-type mice before injury. The antithrombotic effect of the r-hu ADAMTS13, although highly statistically significant, varied among the animals (Fig. 7). Some mice did not respond to r-hu ADAMTS13 treatment. It is possible that in these mice r-hu ADAMTS13 was proteolytically inactivated by thrombin and plasmin (44) produced at the sites of vascular injury. IL-6 (39) and high amounts of VWF released after inflammation (45) or injury could also reduce ADAMTS13 activity. Infusion of the r-hu ADAMTS13 protein into the histamine-challenged Adamts13−/− mice inhibited platelet string and aggregate formation in the activated venules. In vivo, similar to in vitro (46), ADAMTS13 appears to interact with endothelial UL-VWF. Collectively, our findings suggest that ADAMTS13 could have both antithrombotic as well as thrombo-destabilizing activity. In the thrombus, ADAMTS13 could be cleaving the UL-VWF multimers released from platelets into less adhesive smaller fragments and/or directly cleaving the VWF molecules bridging the platelets. However, we also cannot exclude the possibility that there may be another substrate for ADAMTS13 that is important in thrombus formation.

In summary, our results suggest that in vivo ADAMTS13 is active at both low venous and high arterial shear stress conditions. It cleaves platelet strings and regulates platelet interaction with the “activated” vessel wall in the venules, prevents thrombi in activated microvenules, and modulates the thrombotic response in injured arterioles. The antithrombotic effect of ADAMTS13 suggests that in addition to TTP, recombinant...
ADAMTS13 could also be used to treat patients suffering from thrombotic disorders as a result of other hereditary defects, inflammatory disease, or septic conditions.

**MATERIALS AND METHODS**

**Animals.** Mice used in this study were siblings obtained from crosses of Adamts13−/− mice on C57BL/6j/129Sv background (20). The mice of pure C57BL/6j background were purchased from The Jackson Laboratory and β3 integrin−/− mice (32) on BALB/c background were a gift from R. Hynes (Massachusetts Institute of Technology, Cambridge, MA). The mice used for intravital microscopy were young mice (~4 wk old), both male and female, weighing 14–18 g. Infused platelets were isolated from 4–6-mo-old mice of the same genotype. Animals were bred and housed at the CBR Institute for Biomedical Research and all experimental procedures were approved by its Animal Care and Use Committee.

**Blood sampling and platelet preparation.** Blood was harvested from the retro-orbital venous plexus by puncture and collected in 1.5-ml polypropylene tubes containing 300 μl of heparin (30 U/ml). Platelet-rich plasma was obtained by centrifugation at 1,200 revolutions/min for 5 min. The plasma and buffy coat containing some RBCs were gently transferred to fresh polypropylene tubes and centrifuged at 1,200 revolutions/min for 5 min. The platelet-rich plasma was transferred to fresh tubes containing 2 μl of PGI1 (2 μg/ml) and incubated at 37°C for 5 min. After centrifugation at 2,800 revolutions/min, pellets were resuspended in 1 ml of modified Tyrode-Hepes buffer (137 mM NaCl, 0.3 mM Na2HPO4, 2 mM KCl, 12 mM NaHCO3, 5 mM Hepes, 5 mM glucose, 0.35% BSA) containing 2 μl of PGI1 and incubated at 37°C for 5 min. The suspended pellet was centrifuged at 2,800 revolutions/min for 5 min. To remove PGI1, the washing step was repeated twice and platelets were fluorescently labeled with calcine AM 2.5 μg/ml (Invitrogen) for 10 min at room temperature.

**Polyclonal anti-ADAMTS13 production and purification.** Polyclonal rabbit anti-human ADAMTS13 IgG was produced by Baxter Bioscience. The antibody was obtained by immunization of New Zealand white rabbits with purified r-hu ADAMTS13, COOH-terminally tagged with six His residues. Two rabbits were immunized by injection of 20 μg of r-hu ADAMTS13 (6-His) in 200 μl of complete Freund’s adjuvant. The animals were boosted after 2, 4, and 6 wk by injecting 20 μg of r-hu ADAMTS13 (6-His) in 200 μl of incomplete Freund’s adjuvant. After 8 wk, the rabbits were killed and bled. IgG antibodies were purified by protein G affinity chromatography (HiTrap protein G HP column; GE Healthcare) and formulated in PBS.

**Thrombosis in microvenules.** Intravital microscopy was as performed as described previously (47). In brief, mice were anesthetized with 2.5% tribromoethanol (0.15 ml/10 g) and an incision was made through the abdominal wall to expose the mesentery and arterioles of~100 μm diameter were studied. Purified rabbit polyclonal anti-human ADAMTS13 antibody (5 mg/kg mouse) was dissolved in PBS. Control rabbit IgG (Sigma-Aldrich) was injected i.p. to stimulate the endothelium. 100 μl (0.2 mg/ml) of Rhodamine 6G (Sigma-Aldrich) was injected i.v. to label the endothelial platelets and leukocytes before surgery and imaging.

**Thrombus in arterioles.** A previously described model was used with slight modifications (30). In brief, mice were anesthetized with 2.5% tribromoethanol (0.15 ml/10 g) and fluorescent platelets (0.25 × 107 platelets/kg) were infused through the retro-orbital plexus of the eye. An incision was made through the abdominal wall to expose the mesentery, and arterioles of~100 μm diameter were studied. The shear rate was calculated as described previously (48). Arterioles were visualized using the aforementioned microscope, equipped with a 100-W HBO fluorescent lamp source (Optic Quip). Whatman paper saturated with FeCl3 (10%) solution was applied topically for 5 min, which induced demudation of the endothelium, and the vessel was monitored for 40 min after injury or until occlusion. One arteriole was chosen per mouse.

**Quantitative analysis of arteriolar thrombus.** Analysis of the recorded tape was performed blinded to the genotype. We evaluated (1) single platelet–vessel wall interaction determined as the number of fluorescent platelets that deposited on the 250 μm vessel wall segment during 1 min (2–3 min after injury). Quantitative analysis was performed using the following factors: platelet counts >100 were counted as 100 for statistics, (2) the time required for formation of a thrombus >30 μm, (3) thrombus stability by determining the number of thrombi of diameter >30 μm embolizing before vessel occlusion, (4) occlusion time of the vessel, that is, time required for blood to stop flowing for 10 s, and (5) site of vessel occlusion, that is, at the site of injury or downstream.

**r-hu ADAMTS13 infusion.** r-hu ADAMTS13 protein was dissolved in 150 mmol NaCl/20 mmol histidin/2% sucrose/0.05% Crillet 4HP, Tween 80, pH 7.4 (Baxter Bioscience). r-hu ADAMTS13 (3,460 U/kg mouse) was injected i.v. Levels of human ADAMTS13 antigen were determined by a slight modification of the ELISA method described by Rieger et al. (49) and r-hu ADAMTS13 activity was determined according to Gerristen et al. (50). 1 U corresponds to the level of ADAMTS13 activity in pooled normal human plasma.

**Flow chamber studies.** Flow chamber studies were performed as described previously (51). In brief, platelets were isolated from heparinized whole blood, washed in modified Tyrode–Hepes buffer, and labeled with 2.5 μg/ml calcine. Platelet-poor whole blood was reconstituted with labeled platelets before perfusion in a parallel-plate flow chamber system coated with 100 μg/ml collagen Horn (NYCOMED) for 1 h at room temperature. Where indicated, samples were pretreated with 30 μg/ml JON/A (emfret Analytics) (31) for 10 min before perfusion. Platelet adhesion was visualized with an Axiovert 135 inverted microscope (Carl Zeiss Microimaging, Inc.). The percentage of surface area covered by fluorescent platelets was analyzed using National Institutes of Health Image 1.61 software by an individual blinded to genotypes.

**Statistical analysis.** Results are reported as the mean ± SEM. The statistical significance of the difference between means was assessed by the Student’s t test.

**Online supplemental material.** Video 1 shows stimulated release of Weibel-Palade bodies in a microvenule of an ADAMTS13−/− mouse leads to rapid formation of thrombi that embolize downstream. Video 2 depicts arteriolar injury in an ADAMTS13−/− mouse that results in rapid vessel occlusion and infusion of r-hu ADAMTS13 inhibits thrombus growth. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20051732/DC1.

We thank L. Cowan for help in preparing the manuscript.

This work was supported by the National Institutes of Health, National Heart, Lung, and Blood Institute grant nos. R37 HL41002 [to D.D. Wagner] and R01.
REFERENCES

1. Sadler, J.E., J.L. Moake, T. Miyata, and J.N. George. 2004. Recent advances in thrombotic thrombocytopenic purpura. Hematology (Am. Soc. Hematol. Educ. Program). 2004:407–423.

2. Moake, J.L. 2002. Thrombotic microangiopathies. N. Engl. J. Med. 347:589–600.

3. Moake, J.L., C.K. Rudy, J.H. Troll, M.J. Weinstein, I. Moore, L. Fish, G. Raines, M. Deluca, and H. Wu. 2004. Annihilation of large, biologically potent von Willebrand factor multimers. J. Biol. Chem. 279:52434–52441.

4. Furlan, M., R. Robles, M. Galbusera, G. Remuzzi, P.A. Kyrle, B. Brenner, M. Wassmer, V. Aumann, U. Mittler, et al. 1998. Decreased clearance of von Willebrand factor in chronic thrombocytopenic purpura. Blood. 91:2839–2846.

5. Furlan, M., R. Robles, M. Solenthaler, M. Wassmer, P. Sandoz, and B. Lammle. 1997. Deficient activity of von Willebrand factor in chronic relapsing thrombocytopenic purpura. Blood. 89:3097–3103.

6. Tsai, H.M., and E.C. Lian. 1998. Antibodies to von Willebrand factor-cleaving protease in acute thrombocytopenic purpura. N. Engl. J. Med. 339:1578–1584.

7. Furlan, M., R. Robles, M. Solenthaler, and B. Lammle. 1996. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 87:4223–4234.

8. Tsai, H.M. 1996. Physiologic cleavage of von Willebrand factor by a plasma protease dependent on its conformation and requires calcium ion. Blood. 87:4235–4244.

9. Furlan, M., R. Robles, M. Solenthaler, and B. Lammle. 1996. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombocytopenic purpura. Blood. 91:2839–2846.

10. Levy, G.G., W.C. Nichols, E.C. Lian, T. Foroud, J.N. McClintick, B.M. McGee, A.Y. Yang, D.R. Sieniawski, K.R. Stark, R. Gruppo, et al. 2001. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 413:488–494.

11. Soejima, K., N. Mimura, M. Harishima, H. Maeda, T. Hamamoto, T. Nakagaki, and C. Nozaki. 2001. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? J. Biochem. (Tokyo). 130:475–480.

12. Zheng, X., D. Chung, T.K. Takayama, E.M. Majerus, J.E. Sadler, and K. Fujikawa. 2001. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J. Biol. Chem. 276:41059–41063.

13. Uemura, M., K. Tatsumi, M. Matsumoto, M. Fujimoto, T. Matsuyama, M. Ishikawa, T.A. Iwamoto, T. Mori, A. Watanak, H. Fukui, and Y. Fujigawa. 2005. Localization of ADAMTS13 to the settle cells of human liver. Blood. 106:922–924.

14. Zhou, W., M. Inada, T.P. Lee, D. Bentsen, S. Lyubsky, E.E. Boulahsour, S. Gupta, and H.M. Tsai. 2005. ADAMTS13 is expressed in hepatic settle cells. Lab. Invest. 85:780–788.

15. Schefflinger, F., P. Knobl, B. Trattner, B. Plaimauer, G. Mohr, M. Dockal, F. Dorner, and M. Rieger. 2003. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood. 102:3241–3243.

16. Sporn, L.A., V.J. Marder, and D.D. Wagner. 1986. Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell. 46:185–190.

17. Dent, J.A., M. Galbusera, and Z.M. Ruggeri. 1991. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. J. Clin. Invest. 88:774–782.
35. Soejima, K., M. Matsumoto, K. Kokame, H. Yagi, H. Ishizashi, H. Maeda, C. Nozaki, T. Miyata, Y. Fujisawa, and T. Nakagaki. 2003. ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. Blood. 102:3232–3237.

36. Klaus, C., B. Plaimauer, J.D. Studt, F. Dorner, B. Lammle, P.M. Mannucci, and F. Scheiffl erger. 2004. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood. 103:4514–4519.

37. Padilla, A., J.L. Moake, A. Bernardo, C. Ball, Y. Wang, M. Arya, L. Nolasco, N. Turner, M.C. Berndt, B. Anvari, et al. 2004. P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface. Blood. 103:2150–2156.

38. Hamilton, K.K., and P.J. Sims. 1987. Changes in cytosolic Ca2+ associated with von Willebrand factor release in human endothelial cells exposed to histamine. Study of microcarrier cell monolayers using the fluorescent probe indo-1. J. Clin. Invest. 79:600–608.

39. Bernardo, A., C. Ball, L. Nolasco, J.F. Moake, and J.F. Dong. 2004. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood. 104:100–106.

40. Dole, V.S., W. Bergmeier, H.A. Mitchell, S.C. Eichenberger, and D.D. Wagner. 2005. Activated platelets induce Weibel-Palade-body secretion and leukocyte rolling in vivo: role of P-selectin. Blood. 106:2334–2339.

41. Nishio, K., P.J. Anderson, X.L. Zheng, and J.E. Sadler. 2004. Binding of platelet glycoprotein Ib alpha to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13. Proc. Natl. Acad. Sci. USA. 101:10578–10583.

42. Ruggeri, Z.M., J.A. Dent, and E. Saldivar. 1999. Contribution of distinct adhesive interactions to platelet aggregation in flowing blood. Blood. 94:172–178.

43. Savage, B., F. Alnus-Jacobs, and Z.M. Ruggeri. 1998. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell. 94:657–666.

44. Czerny, J.T., J.K. Lam, J.B. Rance, L.R. Mollica, J.S. O’Donnell, and D.A. Lane. 2008. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood. 105:1085–1093.

45. Reiter, R.A., K. Varadi, P.L. Turecek, B. Jilma, and P. Knobl. 2005. Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation. Thromb. Haemost. 93:554–558.

46. Dong, J.F., J.L. Moake, A. Bernardo, K. Fujikawa, C. Ball, L. Nolasco, J.A. Lopez, and M.A. Cruz. 2003. ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. J. Biol. Chem. 278:29633–29639.

47. Frenette, P.S., R.C. Johnson, R.O. Hynes, and D.D. Wagner. 1995. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc. Natl. Acad. Sci. USA. 92:7450–7454.

48. Frenette, P.S., C. Moyna, D.W. Hartwell, J.B. Lowe, R.O. Hynes, and D.D. Wagner. 1998. Platelet-endothelial interactions in inflamed mesenteric venules. Blood. 91:1318–1324.

49. Rieger, M., S. Ferrari, J.A. Kremer Hovinga, C. Konetschny, A. Herzog, L. Koller, A. Weber, G. Renucci, M. Dockal, B. Plaimauer and F. Scheiffl erger. 2006. Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA). Thromb. Haemost. 95:212–220.

50. Gerritsen, H.E., P.L. Turecek, H.P. Schwarz, B. Lammle, and M. Furlan. 1999. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb. Haemost. 82:1386–1389.

51. Bergmeier, W., P.C. Burger, C.L. Pittath, K.M. Hoffmeister, J.H. Hartwig, B. Nieswandt, and D.D. Wagner. 2003. Metalloprotease inhibitors improve the recovery and hemostatic function of in vitro-aged or -injured mouse platelets. Blood. 102:4229–4235.